Please login to the form below

Not currently logged in
Email:
Password:

BMS/Gilead HIV deal

Bristol-Myers Squibb and Gilead Sciences sign licensing agreement to develop and market a new fixed-dose combination HIV treatment

Bristol-Myers Squibb (BMS) and Gilead Sciences have signed a licensing agreement to develop and market a new fixed-dose combination HIV treatment.

The therapy contains BMS' protease inhibitor Reyataz (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

Gilead is currently studying atazanavir and cobicistat in phase II and III studies in HIV-1 treatment-naïve patients.

Under the terms of the agreement, BMS will pay Gilead an undisclosed royalty based on annual net sales of the product.

BMS will be responsible for the formulation, manufacturing, development, registration, distribution, and commercialisation of the fixed-dose combination worldwide.

Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.

Dr Elliott Sigal, executive vice president, chief scientific officer and president, R&D, BMS, said: "A Reyataz and cobicistat fixed-dose combination has the potential not only to help simplify HIV therapy but also to address an unmet medical need in HIV for additional, innovative treatment options."

27th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics